Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia

Clinical Trial

Douglas W Losordo et al. Circulation. 2002.

Abstract

Background: This phase 1/2 study investigated the safety of percutaneous catheter-based gene transfer of naked plasmid DNA encoding for vascular endothelial growth factor 2 (phVEGF2) to left ventricular (LV) myocardium in a prospective, randomized, double-blind, placebo-controlled, dose-escalating study of inoperable patients with class III or IV angina.

Methods and results: A steerable deflectable 8F catheter with a 27-gauge needle at its distal tip was advanced percutaneously to the endocardial surface of the LV in 19 patients (age, 61+/-2 years) with chronic myocardial ischemia who were not candidates for conventional revascularization. Patients were randomized in a double-blind fashion to receive 6 injections (total volume, 6.0 mL) of placebo or phVEGF2 in doses of 200 microg (n=9), 800 microg (n=9), or 2000 microg (n=1) guided by LV electromechanical (NOGA) mapping with a gene-to-placebo ratio of 2:1. A total of 114 LV injections were delivered and caused no hemodynamic alterations, sustained ventricular arrhythmias, ECG evidence of infarction, or ventricular perforation. End-point analysis at 12 weeks disclosed a statistically significant improvement in Canadian Cardiovascular Society (CCS) angina class in phVEGF2-treated versus placebo-treated patients (-1.3 versus -0.1, P=0.04). Remaining efficacy end points--including change in exercise duration (91.8 versus 3.9 seconds), functional improvement by > or =2 CCS classes (9 of 12 versus 1 of 6), and Seattle Angina Questionnaire data--all showed strong trends favoring efficacy of phVEGF2 versus placebo treatment.

Conclusions: This phase 1/2, double-blind, randomized trial provides preliminary data that support safety of phVEGF2 catheter-mediated myocardial gene transfer. The statistically significant reduction in anginal class and strong positive trends for remaining end points suggest that a larger phase 2/3 trial is warranted.

PubMed Disclaimer

Cited by

Novel molecular approaches to cystic fibrosis gene therapy.
Lee TW, Matthews DA, Blair GE. Lee TW, et al. Biochem J. 2005 Apr 1;387(Pt 1):1-15. doi: 10.1042/BJ20041923. Biochem J. 2005. PMID: 15656784 Free PMC article. Review.
Real time magnetic resonance guided endomyocardial local delivery.
Corti R, Badimon J, Mizsei G, Macaluso F, Lee M, Licato P, Viles-Gonzalez JF, Fuster V, Sherman W. Corti R, et al. Heart. 2005 Mar;91(3):348-53. doi: 10.1136/hrt.2004.034363. Heart. 2005. PMID: 15710717 Free PMC article.
Permanent coronary artery occlusion: cardiovascular MR imaging is platform for percutaneous transendocardial delivery and assessment of gene therapy in canine model.
Saeed M, Martin A, Jacquier A, Bucknor M, Saloner D, Do L, Ursell P, Su H, Kan YW, Higgins CB. Saeed M, et al. Radiology. 2008 Nov;249(2):560-71. doi: 10.1148/radiol.2491072068. Epub 2008 Sep 9. Radiology. 2008. PMID: 18780824 Free PMC article.
Receptor tyrosine kinase-mediated angiogenesis.
Jeltsch M, Leppänen VM, Saharinen P, Alitalo K. Jeltsch M, et al. Cold Spring Harb Perspect Biol. 2013 Sep 1;5(9):a009183. doi: 10.1101/cshperspect.a009183. Cold Spring Harb Perspect Biol. 2013. PMID: 24003209 Free PMC article. Review.
Angiogenic gene therapy in cardiovascular diseases: dream or vision?
Ylä-Herttuala S, Bridges C, Katz MG, Korpisalo P. Ylä-Herttuala S, et al. Eur Heart J. 2017 May 7;38(18):1365-1371. doi: 10.1093/eurheartj/ehw547. Eur Heart J. 2017. PMID: 28073865 Free PMC article. Review.

Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia - PubMed (original) (raw)